PRESS RELEASE published on 08/15/2023 at 07:25, 2 years 7 months ago Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
PRESS RELEASE published on 07/18/2023 at 12:26, 2 years 8 months ago Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 06/30/2023 at 07:15, 2 years 8 months ago Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
PRESS RELEASE published on 06/26/2023 at 17:31, 2 years 8 months ago Spexis announces the results of its Annual General Meeting 2023
PRESS RELEASE published on 06/07/2023 at 07:30, 2 years 9 months ago Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances
PRESS RELEASE published on 05/30/2023 at 07:15, 2 years 9 months ago Spexis provides business update and announces financial results for the full year 2022
PRESS RELEASE published on 04/28/2023 at 07:20, 2 years 10 months ago Spexis has received temporary approval of an extension until 31 of May 2023 for the disclosure obligation in connection with the publication and the filing of the annual report 2022.
PRESS RELEASE published on 04/18/2023 at 07:15, 2 years 11 months ago Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
PRESS RELEASE published on 02/08/2023 at 07:20, 3 years 1 month ago Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®
PRESS RELEASE published on 01/25/2023 at 12:56, 3 years 1 month ago Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy
Published on 03/23/2026 at 08:00, 3 hours 19 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 9 hours 19 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 11:06, 12 minutes ago Aroundtown SA: Release of a capital market information
Published on 03/23/2026 at 11:05, 14 minutes ago ASUS Unveils Complete Portfolio Support for Intel® Core™ 200S Series
Published on 03/23/2026 at 11:05, 14 minutes ago BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology
Published on 03/23/2026 at 10:30, 49 minutes ago TK Elevator appoints Brad Selleck as Chief Operating Officer; Vincent Della Valle to retire
Published on 03/23/2026 at 10:30, 49 minutes ago TK Elevator creates the role of Chief Legal Officer, appoints Lars Sjobring
Published on 03/23/2026 at 08:10, 3 hours 9 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 16 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 16 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 17 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 17 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
